Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (113)	8/16/1998 2:52:00 PM
From: Grainne	Read Replies (1) \| Respond to of 666

Thanks for the very interesting stuff from Coulter's prospectus, Pseudo. I am curious as to what ways the TAP approach is significantly different from all of the other cancer therapies in clinical trials at the moment. They all sound quite logical and hopeful, but they are beginning to sound a little similar as well. Also, does anyone know anything about the university in Belgium where the experiments are being done? Does it have a good reputation for experimental medicine? I wonder what the logic is of choosing a site so far removed geographically from Coulter's location in northern California. Any ideas on that?